Advertisement

Association between a prior cancer history and prognosis in adult patients with high‑grade glioma

  • Author Footnotes
    1 Dongjie He and Peiwen Wu contributed equally to this manuscript.
    Dongjie He
    Footnotes
    1 Dongjie He and Peiwen Wu contributed equally to this manuscript.
    Affiliations
    Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province 710038, People’s Republic of China
    Search for articles by this author
  • Author Footnotes
    1 Dongjie He and Peiwen Wu contributed equally to this manuscript.
    Peiwen Wu
    Footnotes
    1 Dongjie He and Peiwen Wu contributed equally to this manuscript.
    Affiliations
    Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province 710038, People’s Republic of China
    Search for articles by this author
  • Gaiyan Li
    Affiliations
    Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province 710038, People’s Republic of China
    Search for articles by this author
  • Siying Zhu
    Affiliations
    Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province 710038, People’s Republic of China
    Search for articles by this author
  • Qiming Wang
    Affiliations
    Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province 710038, People’s Republic of China
    Search for articles by this author
  • Qiuju Shao
    Affiliations
    Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province 710038, People’s Republic of China
    Search for articles by this author
  • Hao Chang
    Correspondence
    Corresponding author.
    Affiliations
    Department of Radiation Oncology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi Province 710038, People’s Republic of China
    Search for articles by this author
  • Author Footnotes
    1 Dongjie He and Peiwen Wu contributed equally to this manuscript.

      Highlights

      • The aim of the present study was to clarify prognostic of prior cancer history on patients with high-grade glioma.
      • Survival was analyzed using Cox regression and competing risk.
      • Subgroup analysis revealed that prior cancer history was a significant prognostic factor for survival in patients.
      • Patients with a prior history of tumors in clinical trials require careful consideration.

      Abstract

      Patients with a prior cancer history are often excluded from clinical trials. This study aimed to investigate the prognostic impact of prior cancer history on patients with high-grade glioma. Data of patients with high-grade glioma as the first or second primary malignancy were obtained from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM) was performed to balance the heterogeneity baseline characteristics. The survivals of patients with or without prior cancers were analyzed. A total of 46,200 patients were included in this study, 2471 (5.3 %) of whom carried a prior cancer history. Prostate (37.7 %), breast (12.2 %), colon and rectal (7.9 %), and skin (6.9 %) cancers were the most common types of prior cancers. Overall survival rates were similar between patients with and without a prior cancer history (hazard ratio [HR], 1.02; 95 % confidence interval [CI], 0.96–1.08; P = 0.525). However, a prior cancer history served as a protective factor against glioma-specific mortality (sub-distribution HR = 0.90; 95 % CI, 0.84–0.96; P = 0.001) in comparison with having no prior cancer history. The subgroup stratified by time intervals and types of prior cancer history showed that a prior cancer history was not a significant prognostic factor for survival in patients, except for breast cancers within 5 years and prostate cancers over 5 years. Our study shows that except for patients with high-grade gliomas with a history of stable tumors, the inclusion of patients with a prior history of tumors in clinical trials requires careful consideration.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cao W.
        • Chen H.-D.
        • Yu Y.-W.
        • Li N.
        • Chen W.-Q.
        Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020.
        Chin Med J (Engl). 2021; 134 (10/gjsmm8): 783-791
        • Donin N.
        • Filson C.
        • Drakaki A.
        • Tan H.-J.
        • Castillo A.
        • Kwan L.
        • et al.
        Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.
        Cancer. 2016; 122 (10/gfzzfv): 3075-3086
      1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014;16:iv1–63. https://doi.org/10/gj3td6.

        • Fisher J.P.
        • Adamson D.C.
        Current FDA-approved therapies for high-grade malignant gliomas.
        Biomedicines. 2021; 9 (10/gpjz5r): 324
        • Liu P.
        • Liu G.
        • Wang G.
        • Zhou W.
        • Sun Y.
        • Chen W.
        • et al.
        Comparison of dosimetric gains provided by intensity-modulated radiotherapy, volume-modulated arc therapy, and helical tomotherapy for high-grade glioma.
        Biomed Res Int. 2020; 2020 (10/gpj2gf): 1-9
        • Strowd R.E.
        • Abuali I.
        • Ye X.
        • Lu Y.
        • Grossman S.A.
        The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
        J Neurooncol. 2016; 127 (10/f8cd46): 165-171
        • Pruitt S.L.
        • Zhu H.
        • Heitjan D.F.
        • Rahimi A.
        • Maddineni B.
        • Tavakkoli A.
        • et al.
        Survival of women diagnosed with breast cancer and who have survived a previous cancer.
        Breast Cancer Res Treat. 2021; 187 (10/gphs8c): 853-865
        • Pruitt S.L.
        • Gerber D.E.
        • Zhu H.
        • Heitjan D.F.
        • Maddineni B.
        • Xiong D.
        • et al.
        Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer.
        Cancer Med. 2021; 10 (10/gphznj): 4752-4767
        • Kumthekar P.
        • Grimm S.
        • Chandler J.
        • Mehta M.
        • Marymont M.
        • Levy R.
        • et al.
        A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
        J Neurooncol. 2017; 133 (10/gbrg7s): 589-594
        • Hottinger A.F.
        • Aissa A.B.
        • Espeli V.
        • Squiban D.
        • Dunkel N.
        • Vargas M.I.
        • et al.
        Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
        Br J Cancer. 2014; 110 (10/f56ds2): 2655-2661
        • Ali A.N.
        • Zhang P.
        • Yung W.K.A.
        • Chen Y.
        • Movsas B.
        • Urtasun R.C.
        • et al.
        NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
        J Neurooncol. 2018; 137 (10/gc5frh): 39-47
        • Villani V.
        • Pace A.
        • Vidiri A.
        • Tanzilli A.
        • Sperati F.
        • Terrenato I.
        • et al.
        Phase II study of weekly carboplatin in pretreated adult malignant gliomas.
        J Neurooncol. 2019; 144 (10/gpj2n9): 211-216
        • He C.
        • Zhang Y.
        • Cai Z.
        • Lin X.
        Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis.
        BMC Cancer. 2019; 19 (10/gpk4qq): 509
        • Wen L.
        • Yu K.
        • Lu H.
        • Zhong G.
        Impact of prior cancer history on survival of patients with gastric cancer.
        Eur J Surg Oncol. 2021; 47 (10/gphzqp): 2286-2294
        • Wang Y.-Q.
        • Lv J.-W.
        • Tang L.-L.
        • Du X.-J.
        • Chen L.
        • Li W.-F.
        • et al.
        Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual.
        Oral Oncol. 2019; 90 (10/gpm7kb): 23-29
        • Doyle J.
        • Khalafallah A.M.
        • Yang W.
        • Sun Y.
        • Bettegowda C.
        • Mukherjee D.
        Association between extent of resection on survival in adult brainstem high-grade glioma patients.
        J Neurooncol. 2019; 145 (10/gpjqh7): 479-486
        • Zhu K.
        • Lin R.
        • Zhang Z.
        • Chen H.
        • Rao X.
        Impact of prior cancer history on the survival of patients with larynx cancer.
        BMC Cancer. 2020; 20 (10/gpk4m9): 1137
      2. Zhou H, Zhang Y, Liu J, Fang W, Yang Y, Hong S, et al. Impact of prior cancer on outcomes in nasopharyngeal carcinoma. Ann Transl Med 2019;7:299–299. https://doi.org/10/gpmz7s.

        • Lin Q.
        • Bao J.-H.
        • Xue F.
        • Qin J.-J.
        • Chen Z.
        • Chen Z.-R.
        • et al.
        The risk of heart disease-related death among anaplastic astrocytoma patients after chemotherapy: a SEER population-based analysis.
        Front Oncol. 2022; 12 (10/gqkdjz)870843
        • Yang Q.-L.
        • Zheng J.-Z.
        • Chen W.-Y.
        • Chen X.-H.
        • Wen D.-L.
        • Chen W.-X.
        • et al.
        Association between preadmission metformin use and outcomes in intensive care unit patients with sepsis and type 2 diabetes: a cohort study.
        Front Med. 2021; 8 (10/gm8899)640785
      3. Lin J, Bytnar JA, Theeler BJ, McGlynn KA, Shriver CD, Zhu K. Survival among glioma patients in the U.S. Military Health System: a comparison with patients in the surveillance, epidemiology, and end results (SEER) Program. Cancer 2020;126:3053–60. https://doi.org/10/gpmx5c.

        • Wang G.-M.
        • Cioffi G.
        • Patil N.
        • Waite K.A.
        • Lanese R.
        • Ostrom Q.T.
        • et al.
        Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
        Neuro-Oncology. 2022; 24 (10/gpj2gn): 302-310
        • He X.
        • Li Y.
        • Su T.
        • Lai S.
        • Wu W.
        • Chen L.
        • et al.
        The impact of a history of cancer on pancreatic ductal adenocarcinoma survival.
        United European Gastroenterol J. 2018; 6 (10/gdvrdg): 888-894
        • Bian X.
        • He X.
        • Yang L.
        • Wu W.
        • Li L.
        Prognosis of hepatocellular carcinoma among cancer survivors with other types of primary tumors.
        Dig Dis Sci. 2020; 65 (10/gjhvj4): 2140-2147
        • Pfeiffer R.M.
        • Webb-Vargas Y.
        • Wheeler W.
        • Gail M.H.
        Proportion of U.S. Trends in breast cancer incidence attributable to long-term changes in risk factor distributions.
        Cancer Epidemiol Biomarkers Prev. 2018; 27 (10/gpm2d7): 1214-1222
        • Fowler M.E.
        • Akinyemiju T.F.
        Meta-analysis of the association between dietary inflammatory index (DII) and cancer outcomes.
        Int J Cancer. 2017; 141 (10/gb4j8d): 2215-2227
        • Chang S.M.
        • Barker F.G.
        • Schmidt M.H.
        • Sloan A.E.
        • Kasper R.
        • Phillips L.
        • et al.
        Clinical trial participation among patients enrolled in the Glioma Outcomes Project.
        Cancer. 2002; 94 (10/cgn4qx): 2681-2687
        • Al-Husseini M.J.
        • Saad A.M.
        • El-Shewy K.M.
        • Nissan N.E.
        • Gad M.M.
        • Alzuabi M.A.
        • et al.
        Prior malignancy impact on survival outcomes of glioblastoma multiforme; population-based study.
        Int J Neurosci. 2019; 129 (10/gpnm4x): 447-454
        • Wu S.
        • Peng G.
        • Liang W.
        • He J.
        Impact of prior cancer history on outcomes in thymoma: a propensity score, population-based study.
        Gland Surg. 2021; 10 (10/gkxzrk): 1618-1626
        • Perez M.
        • Murphy C.C.
        • Pruitt S.L.
        • Rashdan S.
        • Rahimi A.
        • Gerber D.E.
        Potential impact of revised NCI eligibility criteria guidance: prior malignancy exclusion in breast cancer clinical trials.
        J Natl Compr Canc Netw. 2022; 20 (10/gqknv3): 792-799.e4
        • Chen K.
        • Tian L.
        • Li Y.
        • Jin Y.
        • Liu H.
        • Wang H.
        Impact of prior cancer on the prognosis of patients with laryngeal cancer: a population-based study using the surveillance, epidemiology, and end results database.
        Front Oncol. 2020; 10 (10/gpnm54)561330
        • Chen H.
        • Yan L.
        • Pu S.
        • Zhu L.
        • Zhang H.
        • Zhou C.
        Research on effectiveness of prior cancer on survival outcomes for patients with nonmetastatic triple-negative breast cancer: a competing risk analysis and propensity score matching analysis of the SEER database.
        J Oncol. 2021; 2021 (10/gpnndd): 1-12
        • Burri S.H.
        • Prabhu R.S.
        • Sumrall A.L.
        • Brick W.
        • Blaker B.D.
        • Heideman B.E.
        • et al.
        BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
        J Neurooncol. 2015; 123 (10/f7dxnt): 259-266
        • Hwang K.
        • Kim T.M.
        • Park C.-K.
        • Chang J.H.
        • Jung T.-Y.
        • Kim J.H.
        • et al.
        Concurrent and adjuvant temozolomide for newly diagnosed grade III gliomas without 1p/19q Co-deletion: a randomized, open-label, phase 2 study (KNOG-1101 Study).
        Cancer Res Treat. 2020; 52 (10/gpj2f9): 505-515
        • Lin C.
        • Wu J.
        • Ding S.
        • Goh C.
        • Andriani L.
        • Shen K.
        • et al.
        Impact of prior cancer history on the clinical outcomes in advanced breast cancer: a propensity score-adjusted, Population-Based Study.
        Cancer Res Treat. 2020; 52 (10/gqkc9z): 552-562